Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3241
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Expression of Immune Checkpoint Molecules in Endometrial Carcinoma

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2015English

Immune Response Characterization of Endometrial Cancer

Oncotarget
Oncology
2019English

Survival Outcomes in Patients With Undifferentiated Endometrial Carcinoma

Dicle Tıp Dergisi
2019English

Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Impact of Histological Subtype on Outcomes of Renal Cell Carcinoma Patients

Journal of Drug Assessment
2018English

Breast Carcinoma in Situ: An Observational Study of Tumor Subtype, Treatment and Outcomes

Oncotarget
Oncology
2016English

Clinicopathological and Molecular Analysis of Endometrial Carcinoma Associated With Tamoxifen

Modern Pathology
Forensic MedicinePathology
2008English

Β-Catenin and E-Cadherin Expression Patterns in High-Grade Endometrial Carcinoma Are Associated With Histological Subtype

Modern Pathology
Forensic MedicinePathology
2002English

Endometrial Serous Carcinoma: Its Molecular Characteristics and Histology-Specific Treatment Strategies

Cancers
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy